Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ammonia-dependent NAD synthetase, commonly referred to as NadE, is a critical enzyme that catalyzes the final step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). This enzyme facilitates the ATP-dependent amidation of nicotinic acid adenine dinucleotide (NaAD) using ammonia as the nitrogen donor. It is essential for the survival of various bacterial pathogens, including Mycobacterium tuberculosis and Staphylococcus aureus, as NAD+ is a vital cofactor for numerous metabolic and regulatory processes. Because many bacteria rely on this ammonia-dependent form while humans utilize a glutamine-dependent version (NADSYN1), NadE is a promising target for the development of selective antibacterial agents. Inhibiting NadE disrupts the cellular energy balance and redox homeostasis, making it a potent focal point for treating multi-drug resistant infections.
Inhibition of the ATP-dependent amidation of nicotinic acid adenine dinucleotide (NaAD) to nicotinamide adenine dinucleotide (NAD+), leading to depletion of essential NAD+ levels and bacterial cell death.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ammonia-dependent NAD synthetase (NadE).